GSK lung 'wonder drug' gets green light
Shares in GSK were up more than 3pc on Thursday after a US panel approved a new drug, developed to treat smoking-related lung damage. The US Food and Drug Administration may still delay final approval of Breo Ellipta, according to analysts, but an advisory panel to the American regulator gave the …